• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

    0.0660 -0.0071 (-9.71%)
    Streaming Delayed Price Updated: 1:46 PM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Propanc Biopharma, Inc. - Common Stock

    News headline image
    Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
    Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
    From Rosen Law Firm
    Via Business Wire
    News headline image
    Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
    Fifth Agreement between Propanc & the Universities over a 17yr Period 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
    Root-Cause Attack. Chemo Sensitization. Safer Profile. 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
    A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to Clinic 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
    PRP May Outshine Traditional Therapies in a Booming $4.4 Billion Market 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
    Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
    A World-First, Fully Synthetic Recombinant Version of PRP 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
    The Science, Clinical Promise, & Market Outlook 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Provides Shareholder Update
    CEO Highlights Significant Progress Achieved & Outlines Ambitious Plans for 2026 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
    Joint Research Team Focusing on Impact of PRP Reversal of EMT Pathways as Central Role 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
    Results Underscore PRP Candidacy as a Disruptor of the Tumor Microenvironment 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline
    Initial Investment of $1 Million Received from Hexstone Capital LLC Upon Closing 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
    Initial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
    Initial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.